Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)

Inclusion Criteria:

* Histologically confirmed adenocarcinoma of pancreas metastatic to liver and/or lungs or peritoneal surface. (a.k.a. Stage IV B).
* No prior chemotherapy with Gemzar, Xeloda and Taxotere.
* Measurable disease: Any mass reproducibly measurable in two perpendicular diameters by x-ray, physical examination, CT or MRI scans.
* The following lesions conventionally are not considered measurable:

  * CNS lesions
  * Blastic or lytic bone lesions (which should be documented and followed)
  * Radiated lesions unless progression after RT is documented
* Ineligible for other high priority national or institutional studies
* Prior radiation and surgery allowed:

  * \> 3 weeks since surgery
  * \> 4 weeks since RT
* Non pregnant females who are not breast feeding with a negative serum or urine β-HCG test within 1 week of starting the study. Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter.
* Clinical Parameters:

  * Life expectancy \> 2 months
  * Age 18 - 70 years old
  * Performance status 0-2 (ECOG)
  * Peripheral Neuropathy must be \< grade 1
  * Able to tolerate oral medications
* Required initial laboratory data:

  * Absolute Neutrophil Count \> 1,500 μl
  * White Blood Count \> 3,000/μl
  * Platelet count \> 100,000/μl
  * BUN \< 1.5 x normal
  * Creatinine \< 1.5 normal
  * Hemoglobin \> 8.0 g/dl
  * Serum Albumin \> 3 mg/dl
  * Total Bilirubin \< 2.0 mg/dl
  * SGOT, SGPT, Alkaline Phosphatase SGOT and SGPT may be up to 3.0 x ULN if Alk Phos \< 2.0 x ULN; or Alk Phos may be up to 3.0 x ULN if SGOT and SGPT are \< 2.0 x ULN

Exclusion Criteria:

* Hypersensitivity: Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80 must be excluded.
* Informed Consent: Each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.
* The patient has not had a prior malignancy in last 5 years other than curatively treated carcinoma in-situ of the cervix or non-melanoma skin cancer
* No serious medical or psychiatric illness preventing informed consent or intensive treatment (e.g., serious infection).
* Patients with brain metastases are excluded.
* Patients known to have HIV will be excluded.